Yokota Tomoya
Division of Gastrointestinal Oncology, Shizuoka Cancer Center.
Gan To Kagaku Ryoho. 2019 Jan;46(1):21-27.
Recent breakthrough in cancer immunotherapy employing immune checkpoint inhibitors(ICI)has evolved into number of clinical trials with antibodies against PD-1, PD-L1, and CTLA-4 for patients with squamous cell carcinoma of head and neck (SCCHN). The development of ICI in SCCHN initiated in the recurrent and metastatic setting. CheckMate141 supports nivolumab as a standard therapy for patients with platinum-refractory recurrent and metastatic-SCCHN. KEYNOTE-048 testing pembrolizumab demonstrated future practice-changing data in platinum sensitive recurrent and metastatic-SCCHN. ICI may open the door to a new era of tailor-made medicine in treatment of recurrent and metastatic-SCCHN, based on tumor burden, clinical stability, and PD-L1 status. Furthermore, ICI in combination with concurrent cisplatin based chemoradiotherapy has been investigated for locoregionally advanced disease.
近年来，采用免疫检查点抑制剂（ICI）的癌症免疫疗法取得了突破，已开展了多项针对头颈部鳞状细胞癌（SCCHN）患者的使用抗PD-1、PD-L1和CTLA-4抗体的临床试验。ICI在SCCHN中的研发始于复发和转移的情况。CheckMate141研究支持纳武单抗作为铂类难治性复发和转移性SCCHN患者的标准治疗方法。KEYNOTE-048对头帕博利珠单抗的试验在铂类敏感的复发和转移性SCCHN中展示了未来可能改变治疗方式的数据。基于肿瘤负荷、临床稳定性和PD-L1状态，ICI可能为复发和转移性SCCHN的治疗开启量身定制药物的新时代。此外，已对ICI联合顺铂同步放化疗用于局部晚期疾病进行了研究。
